Maxim Group Upgrades Cyclo Therapeutics Inc - (CYTH)
Fintel reports that on September 27, 2023, Maxim Group upgraded their outlook for Cyclo Therapeutics Inc - (NASDAQ:CYTH) from Hold to Buy .
Analyst Price Forecast Suggests 264.29% Upside
As of March 27, 2023, the average one-year price target for Cyclo Therapeutics Inc - is 5.10. The forecasts range from a low of 5.05 to a high of $5.25. The average price target represents an increase of 264.29% from its latest reported closing price of 1.40.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cyclo Therapeutics Inc - is 3MM, an increase of 220.42%. The projected annual non-GAAP EPS is -1.00.
What is the Fund Sentiment?
There are 22 funds or institutions reporting positions in Cyclo Therapeutics Inc -. This is a decrease of 1 owner(s) or 4.35% in the last quarter. Average portfolio weight of all funds dedicated to CYTH is 0.00%, a decrease of 89.58%. Total shares owned by institutions decreased in the last three months by 53.73% to 456K shares.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 177K shares representing 0.91% ownership of the company. No change in the last quarter.
Geode Capital Management holds 100K shares representing 0.52% ownership of the company. In it's prior filing, the firm reported owning 52K shares, representing an increase of 47.95%. The firm increased its portfolio allocation in CYTH by 228.69% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 80K shares representing 0.42% ownership of the company. In it's prior filing, the firm reported owning 71K shares, representing an increase of 11.42%. The firm increased its portfolio allocation in CYTH by 103.60% over the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 28K shares representing 0.14% ownership of the company. In it's prior filing, the firm reported owning 28K shares, representing a decrease of 1.64%. The firm decreased its portfolio allocation in CYTH by 13.53% over the last quarter.
Renaissance Technologies holds 18K shares representing 0.09% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
Cyclo Therapeutics Background Information
(This description is provided by the company.)
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.